Overview

Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

Status:
Completed

Trial end date:
2020-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to study whether adding Aprepitant to Palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI or FOLFOX chemotherapy regimen among gastrointestinal malignancy patients with high risk factors of chemotherapy-associated adverse events.

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Aprepitant
BB 1101
Dexamethasone
Dexamethasone acetate
Fosaprepitant
Palonosetron